New antibody drug targets stubborn leukemia cells in High-Risk patients
NCT ID NCT05285813
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests a drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of disease after standard treatments. The drug works by helping the immune system find and attack cancer cells. The main goal is to see if the drug can clear these leftover cancer cells or improve blood counts. About 42 people will take part at one center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.